WO2011115264A1 - 経鼻投与用組成物及びその製造方法 - Google Patents
経鼻投与用組成物及びその製造方法 Download PDFInfo
- Publication number
- WO2011115264A1 WO2011115264A1 PCT/JP2011/056625 JP2011056625W WO2011115264A1 WO 2011115264 A1 WO2011115264 A1 WO 2011115264A1 JP 2011056625 W JP2011056625 W JP 2011056625W WO 2011115264 A1 WO2011115264 A1 WO 2011115264A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cellulose acetate
- composition
- peptide
- water
- physiologically active
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 153
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 116
- 229920002301 cellulose acetate Polymers 0.000 claims abstract description 107
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 59
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 claims description 50
- 238000002156 mixing Methods 0.000 claims description 41
- 230000000975 bioactive effect Effects 0.000 claims description 39
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims description 18
- 108010049264 Teriparatide Proteins 0.000 claims description 16
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 claims description 12
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims description 12
- 102000058004 human PTH Human genes 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 101500028621 Homo sapiens Motilin Proteins 0.000 claims description 4
- 101500028774 Homo sapiens Glucagon-like peptide 1 Proteins 0.000 claims description 3
- 230000021736 acetylation Effects 0.000 claims description 3
- 238000006640 acetylation reaction Methods 0.000 claims description 3
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims description 3
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims description 3
- 101500027325 Homo sapiens Atrial natriuretic peptide Proteins 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 229950008486 carperitide Drugs 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 23
- 239000000843 powder Substances 0.000 abstract description 14
- 238000000034 method Methods 0.000 description 44
- 230000000052 comparative effect Effects 0.000 description 40
- 229920002678 cellulose Polymers 0.000 description 33
- 239000001913 cellulose Substances 0.000 description 33
- 239000000243 solution Substances 0.000 description 33
- 239000002245 particle Substances 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 22
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 20
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 20
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 20
- 210000002850 nasal mucosa Anatomy 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 239000003814 drug Substances 0.000 description 15
- 210000003928 nasal cavity Anatomy 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 239000008213 purified water Substances 0.000 description 14
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000000126 substance Substances 0.000 description 11
- 241000282567 Macaca fascicularis Species 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 9
- 210000004877 mucosa Anatomy 0.000 description 9
- 210000004400 mucous membrane Anatomy 0.000 description 7
- 210000003097 mucus Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000003172 expectorant agent Substances 0.000 description 6
- 229940066491 mucolytics Drugs 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 238000005507 spraying Methods 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 239000004570 mortar (masonry) Substances 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- -1 salusin Proteins 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 3
- 229960001008 heparin sodium Drugs 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000001944 turbinate Anatomy 0.000 description 3
- 108010039627 Aprotinin Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- 102100036893 Parathyroid hormone Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000009775 high-speed stirring Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 229940037525 nasal preparations Drugs 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 239000003488 releasing hormone Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- RWBLWXCGQLZKLK-USVTTYPOSA-N (2s)-2-[(2-aminoacetyl)amino]-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxob Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CN)C(C)C)C1=CN=CN1 RWBLWXCGQLZKLK-USVTTYPOSA-N 0.000 description 1
- SULKGYKWHKPPKO-RAJPIYRYSA-N (4s)-4-[[(2r)-2-[[(2s,3r)-2-[[(2s)-4-amino-4-oxo-2-[[(2s)-pyrrolidine-2-carbonyl]amino]butanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-5-[[(2s,3s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s,3r)-1-[[2-[[(1r)-1-carboxy Chemical compound N([C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CS)C(O)=O)[C@@H](C)O)C(=O)[C@@H]1CCCN1 SULKGYKWHKPPKO-RAJPIYRYSA-N 0.000 description 1
- DPEUWKZJZIPZKE-OFANTOPUSA-N 330936-69-1 Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 DPEUWKZJZIPZKE-OFANTOPUSA-N 0.000 description 1
- YKGYIDJEEQRWQH-UHFFFAOYSA-N 4-[6-(diaminomethylideneamino)-1-oxohexoxy]benzoic acid ethyl ester Chemical compound CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)N)C=C1 YKGYIDJEEQRWQH-UHFFFAOYSA-N 0.000 description 1
- CBYGNGZRFGVXDG-UHFFFAOYSA-N 5-[[2-[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]sulfanylacetyl]amino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid Chemical compound C=1C=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(=O)O)=CC=1NC(=O)CSCCC(=O)ON1C(=O)CCC1=O CBYGNGZRFGVXDG-UHFFFAOYSA-N 0.000 description 1
- OJSXICLEROKMBP-FFUDWAICSA-N 869705-22-6 Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OJSXICLEROKMBP-FFUDWAICSA-N 0.000 description 1
- 102400001318 Adrenomedullin Human genes 0.000 description 1
- 101800004616 Adrenomedullin Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 108010052412 Apelin Proteins 0.000 description 1
- 102000018746 Apelin Human genes 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 102400000060 Copeptin Human genes 0.000 description 1
- 101800000115 Copeptin Proteins 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 102400001370 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 102100036519 Gastrin-releasing peptide Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102000012004 Ghrelin Human genes 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 101710173668 Glucagon-4 Proteins 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 102400001367 Guanylin Human genes 0.000 description 1
- 101800004305 Guanylin Proteins 0.000 description 1
- 101000988651 Homo sapiens Humanin-like 1 Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 1
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000002419 Motilin Human genes 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 101800001607 Neuromedin N Proteins 0.000 description 1
- 102400001104 Neuromedin N Human genes 0.000 description 1
- 101800001638 Neuromedin-C Proteins 0.000 description 1
- 102100038813 Neuromedin-U Human genes 0.000 description 1
- 102100025257 Neuropeptide S Human genes 0.000 description 1
- 101710100554 Neuropeptide S Proteins 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 108010018674 Neurophysins Proteins 0.000 description 1
- 102000002710 Neurophysins Human genes 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101800000590 Obestatin Proteins 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010088847 Peptide YY Proteins 0.000 description 1
- 102100029909 Peptide YY Human genes 0.000 description 1
- 102000009087 Prolactin-Releasing Hormone Human genes 0.000 description 1
- 108010087786 Prolactin-Releasing Hormone Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 108010047909 Resistin Proteins 0.000 description 1
- 102100024735 Resistin Human genes 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000005630 Urocortins Human genes 0.000 description 1
- 108010059705 Urocortins Proteins 0.000 description 1
- 108010011107 Urotensins Proteins 0.000 description 1
- 102000026557 Urotensins Human genes 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 1
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 108010042362 beta-Lipotropin Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000003997 corticotropin derivative Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229950000501 gabexate Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000011854 humanin Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000004677 mucosal permeability Effects 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical group C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 108010021512 neuromedin U Proteins 0.000 description 1
- RZMLVIHXZGQADB-YLUGYNJDSA-N neuromedin n Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C1=CC=C(O)C=C1 RZMLVIHXZGQADB-YLUGYNJDSA-N 0.000 description 1
- ZRCUKBVXFDZBKP-XJEBPGRNSA-N neuropepetide s Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 ZRCUKBVXFDZBKP-XJEBPGRNSA-N 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002877 prolactin releasing hormone Substances 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000000777 urocortin Substances 0.000 description 1
- 239000000780 urotensin Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2214—Motilins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Definitions
- the present invention relates to a cellulose acetate powder mainly impregnated with a peptide drug, and relates to a composition in which absorption of a drug from a mucous membrane such as a nose is promoted by using the cellulose acetate powder as a base. . More specifically, the present invention relates to a technique for producing a composition with improved drug absorption from mucous membranes such as the nose, which is produced by adding and mixing cellulose acetate and water to a bioactive peptide as a main ingredient.
- bioactive peptides or bioactive protein preparations such as insulin, growth hormone, atrial natriuretic peptide, calcitonin, LH-RH derivatives, parathyroid hormone, and corticotropin derivatives are being sold as pharmaceuticals.
- these bioactive peptides or bioactive proteins are inactivated by degradation by proteases in the digestive tract, development as oral preparations is difficult, and most of them are mainly used as parenteral preparations. It is provided in the form of a preparation as an injection.
- administration by injection requires patient visits and is painful, a parenteral transmucosal preparation that can be administered painlessly at home is desired.
- Nasal administration is one of the preparation forms suitable for parenteral transmucosal administration.
- the nasal mucosa which is the site of administration, has a developed vascular network, and the upper turbinate, middle turbinate, and lower turbinate mucosa have a large surface area.
- Nasal administration is expected to have higher drug absorption than oral mucosa, rectal mucosa and pulmonary mucosa administration.
- peptide drugs are absorbed from the nasal mucosa
- there are various barriers such as low permeability through the mucosa and degradation of bioactive peptides by enzymes present in mucus.
- Bioavailability hereinafter referred to as BA
- BA Bioavailability
- Conventional methods for improving absorption of bioactive peptides in nasal administration include 1) a method of adding or blending a substance that promotes absorption of bioactive peptides on the nasal mucosa into the composition for administration, and 2) bioactivity.
- a method of adding or blending a substance that inhibits the peptide from being decomposed on the nasal mucosa, or 3) a method of improving the absorption of the physiologically active peptide by extending the residence time of the physiologically active substance on the nasal mucosa Is mentioned.
- a mucolytic agent as a mucosal absorption promoter.
- physiologically active substances such as cytokines, peptide hormones, growth factors, non-water-absorbing and poorly water-soluble cellulose derivatives (for example, ethyl cellulose, cellulose acetate, nitrocellulose, etc.) and N-acetyl.
- a powder nasal preparation with improved absorption by adding or blending a cysteine derivative such as -L-cysteine or a mucolytic agent such as an active SH group-containing alcohol.
- the presence of a non-water-absorbing and poorly water-soluble substance as a base causes the bioactive peptide and the mucolytic agent to adhere and stay on the nasal mucosa. It is described that it dissolves in a small amount of mucus to produce a locally high-concentration solution of bioactive peptide and mucolytic agent.
- Non-patent Document 1 N-acetyl-L-cysteine, which is a mucolytic agent, is reported.
- N-acetyl-L-cysteine which is a mucolytic agent
- JP-A-7-206699 discloses peptide nasal and protein nasal preparations containing gabexate mesylate and famostat mesylate having serine protease inhibitory activity, and discloses that BA improves in these preparations. ing.
- Japanese Patent Publication No. 62-42888 discloses a composition for nasal administration consisting of a polypeptide having physiological activity and a water-absorbing and poorly water-soluble base such as crystalline cellulose, ⁇ -cellulose, and sodium carboxymethylcellulose. Things are listed.
- a water-absorbing and poorly water-soluble base when administered into the nasal cavity, it first absorbs water on the nasal mucosa, and the particles become a viscous liquid state and flow properly. It is disclosed that the high molecular weight polypeptides are in good contact with the nasal mucosa due to dispersion and particles staying at the site of attachment of the nasal mucosa, and thus exhibit high absorbency of the polypeptides.
- JP-A-10-59841 discloses a water-absorbing and hardly water-soluble base such as a physiologically active peptide and crystalline cellulose, and a water-absorbing and gel-forming group such as a certain amount of hydroxypropylcellulose and hydroxymethylcellulose.
- the particle size of the base is 10 ⁇ m to 350 ⁇ m for a water-absorbing and poorly water-soluble base, and in the case of a water-absorbing and gel-forming base, the particle size is By using a 10 to 100 micron base, when administered intranasally, bioactive peptides are widely distributed in the nasal cavity, and the gel-forming base is gelled and stays in the nasal cavity As a result, it has been disclosed to increase the maximum blood concentration of the drug.
- a water-absorbing and poorly water-soluble cellulose derivative particularly crystalline cellulose
- crystalline cellulose as a base that exhibits a high physiologically active peptide BA.
- water-absorbing and poorly water-soluble bases when sprayed into the nasal cavity, may absorb mucous membrane water and cause discomfort such as nasal mums. It was thought that there was a problem from the viewpoint of compliance.
- an object of the present invention is to provide a powdery composition for nasal administration using a base that improves the absorbability of a physiologically active peptide.
- the present inventors For the purpose of developing a nasal preparation with an increased BA of a bioactive peptide, the present inventors have made extensive studies on the selection of a base substance, the preparation method of the preparation and the distribution of the bioactive peptide inside the base particle Went. The present inventor considers that the selection of the base is particularly important among these considerations, and the desirable base characteristic for a formulation that exhibits a high BA in nasal administration of a bioactive peptide is described on the nasal mucosa.
- the cellulose acetate was focused on under the hypothesis that it had to satisfy the conditions such as the appropriate retention and water absorption and excellent retention and release timing of the bioactive peptide.
- the preparation administered to the nasal mucosa stays in the nasal cavity for about 10 to 15 minutes and is gradually discharged into the nasal cavity due to mucoserial clearance.
- a solid mixing method is generally used in which the stability of the bioactive peptide that is the main agent is taken into account and a dry base and the bioactive peptide are mixed. I came.
- the physiologically active peptide only adheres to the particle surface of the base, and when the formulation is administered nasally, the physiologically active peptide on the base surface is in the nasal mucus.
- the present inventor can produce a cellulose acetate preparation having a form in which a physiologically active peptide is also retained inside the base particles by adding an appropriate amount of water to cellulose acetate having low water absorption, 2)
- the bioactive peptide and the base are compared with the nasal formulation BA prepared by the solid mixing method, 3)
- the production method thereof it was clarified that the amount of water added relative to the weight of cellulose acetate was a very important factor for obtaining high BA, and the efficiency of bioactive peptides
- the present invention has been completed as a powdery composition for nasal administration.
- this application includes the following inventions: 1) A composition for nasal administration containing a physiologically active peptide and cellulose acetate as a base. 2) The composition according to 1), wherein the physiologically active peptide is impregnated in a base. 3) The composition according to 1) or 2), wherein the degree of acetylation of cellulose acetate is 32 to 40%. 4) The composition according to any one of 1) to 3), wherein the physiologically active peptide is a peptide having a molecular weight of 20,000 or less.
- the physiologically active peptide is human glucagon-like peptide-1 (GLP-1), human parathyroid hormone, human parathyroid hormone 1-34 (hPTH (1-34)), human motilin, human motilin derivative, human ghrelin, human atrial 4)
- GLP-1 human glucagon-like peptide-1
- hPTH human parathyroid hormone 1-34
- human motilin human motilin derivative
- human ghrelin human atrial
- the composition of natriuretic peptide is produced by mixing a physiologically active peptide, cellulose acetate and water, and then drying the mixture. Production of the composition according to any one of 1) to 5) Method.
- compositions for nasal administration since the retention property on the nasal mucosa is necessary as a desirable base property for the bioactive peptide to exhibit high BA, it is poorly water-soluble and lower than crystalline cellulose, but moderate Conditions such as excellent water absorption characteristics and excellent timing of retention and separation of physiologically active peptides are required. According to the present invention, the use of cellulose acetate as a base satisfying such conditions eliminates the need for other substances to be added or blended, and is safer and superior in usability and absorbs physiologically active peptides. Compositions with improved properties are provided.
- FIG. 1 shows a solution mixture composition of GLP-1 and cellulose acetate (Example 1), a solid mixture composition of GLP-1 and cellulose acetate (Comparative Example 1), and a solution mixture composition of GLP-1 and crystalline cellulose.
- 2 shows the time course of plasma GLP-1 concentration when (Comparative Example 2) is administered nasally to cynomolgus monkeys.
- FIG. 2 shows a solution mixed composition of hPTH (1-34) and cellulose acetate (Example 2), a solid mixed composition of hPTH (1-34) and cellulose acetate (Comparative Example 3), and hPTH (1-34).
- FIG. 2 shows the time course change of plasma PTH concentration when a solution mixture composition of sodium and crystalline cellulose (Comparative Example 4) is administered nasally to cynomolgus monkeys.
- FIG. 3 shows a solution mixture composition of a motilin derivative and cellulose acetate (Example 3), a solid mixture composition of a motilin derivative and cellulose acetate (Comparative Example 5), and a solution mixture composition of a motilin derivative and crystalline cellulose (Comparative Example 6). ) Shows the time course of plasma motilin derivative concentration when administered nasally to cynomolgus monkeys.
- FIG. 3 shows a solution mixture composition of a motilin derivative and cellulose acetate (Example 3), a solid mixture composition of a motilin derivative and cellulose acetate (Comparative Example 5), and a solution mixture composition of a motilin derivative and crystalline cellulose (Comparative Example 6).
- FIG. 4 shows a solution mixture composition in which motilin derivative and cellulose acetate were mixed in purified water of 25 to 500% by weight of cellulose acetate (Examples 4 to 7), and motilin derivative and cellulose acetate were mixed with 5% by weight of cellulose acetate.
- the time-dependent change of the plasma motilin derivative concentration is shown when a solution composition (Comparative Example 7) mixed in purified water and a solid mixed composition of a motilin derivative and cellulose acetate (Comparative Example IV) are administered nasally to cynomolgus monkeys.
- FIG. 7 shows a solution mixture composition in which motilin derivative and cellulose acetate were mixed in purified water of 25 to 500% by weight of cellulose acetate (Examples 4 to 7), and motilin derivative and cellulose acetate were mixed with 5% by weight of cellulose acetate.
- the time-dependent change of the plasma motilin derivative concentration is shown when a solution composition (Comparative Example
- FIG. 5 shows the time course of plasma motilin derivative concentration when a solution mixture composition of cellulose acetate having a motilin derivative and acetyl group content of 32.0% (Example 8) was administered nasally to cynomolgus monkeys.
- FIG. 6 shows the observation results of how the drug is distributed in the cellulose acetate preparation particles using the fluorescence-modified motilin derivative.
- Left column cellulose acetate powder
- middle column composition of Example 10
- right column composition of Comparative Example 9
- upper row transmitted light image
- middle row fluorescent image
- lower row overlay of transmitted light image and fluorescent image .
- the present invention is a powdery composition for nasal administration prepared by mixing cellulose acetate as a base, a physiologically active peptide, and water, followed by a drying treatment method. Provides a composition that provides a sufficiently high BA to exhibit activity in vivo.
- the composition of the present invention retains the physiologically active peptide not only on the surface of the base but also inside the base by impregnating the physiologically active peptide inside the base using the water-absorbing action of cellulose acetate as the base. Can do.
- the composition can be produced by mixing a physiologically active peptide, cellulose acetate and water, and then drying the mixture.
- the order of mixing the physiologically active peptide, cellulose acetate and water is not limited, but the following order can be considered depending on the production process. 1) Add water to a mixture of bioactive peptide and cellulose acetate and mix. 2) After dissolving the physiologically active peptide in water, cellulose acetate is added and mixed.
- the mixing of the base and the physiologically active peptide was performed by mixing by a technique, mixing using a high-speed stirring device, mixing using a revolving / spinning stirring device, or a biaxial planetary mixing kneader. Although there are mixing and the like, any of them can be adopted, but is not limited thereto.
- the composition of the present invention When the composition of the present invention is sprayed or inhaled onto the mucous membrane such as in the nasal cavity, it can be adhered and retained on the mucosa by the cellulose acetate as the base. Then, the cellulose acetate particles staying on the mucous membrane absorb the mucus slightly from the mucosal surface, and the bioactive peptide retained in the cellulose acetate is dissolved in the mucus, so that the bioactive peptide is localized. A high concentration region occurs. In this state, using the concentration gradient of the bioactive peptide, the bioactive peptide can be efficiently reached from the mucosa to the vascular network existing nearby, and the mucosal absorption of the bioactive peptide can be improved.
- the cellulose acetate in the present invention is a semisynthetic polymer obtained by acetic esterification of cellulose, which is generally a natural polymer.
- Cellulose is a long-chain natural polysaccharide in which glucose is linked by ⁇ -1,4-glucoside. If the hydroxyl group of cellulose is modified and esterified or etherified, it becomes thermoplastic, water-soluble or organic solvent plastic, and a molded product can be easily made.
- Regarding the water absorption characteristics of cellulose derivatives for example, by introducing a methyl group into the cellulose molecule, the hydrogen bond between the hydroxyl groups of cellulose is prevented, and the cellulose molecule is hydrated. It is said to improve.
- cellulose acetate having different properties such as water absorption characteristics exists depending on the degree of acetylation of the hydroxyl group of cellulose (acetyl group content) and the degree of polymerization of the cellulose chain.
- cellulose acetate having any acetyl group content and degree of polymerization can be used, but acetic acid having an acetyl group content of 32 to 40% from the viewpoint of appropriate water affinity and water absorption. It is desirable to use cellulose.
- cellulose acetate a commercially available powder product may be used as it is, but a commercially available powder product may be further processed and used as a desired particle diameter and shape.
- a conventional fine particle forming method can be used as appropriate.
- jet mill grinding, hammer mill grinding, rotary ball mill grinding, vibration ball mill grinding, bead mill grinding, shaker mill Method of physical pulverization by pulverization, rod mill pulverization, tube mill pulverization, etc. once cellulose acetate is dissolved in solvent, crystallized by changing temperature, changing solvent composition, etc., and recovered by centrifugation or filtration
- a crystallization method a cellulose acetate is once dissolved in a solvent, sprayed into a drying chamber of a spray dryer using a spray nozzle, and the solvent in the spray solution is volatilized in a short time.
- Cellulose acetate is treated to keep the particle size within a certain range by methods such as sieving, gravity settling, centrifugal force classification, inertial force classification based on the flow of air flow, etc., in order to suppress particle size variation. May be.
- the particle size can be measured using, for example, a laser diffraction particle size distribution measuring device, a sieving and classifying device, or an image analysis type particle size measuring device.
- the average particle diameter of cellulose acetate is usually in the range of 0.1 to 1000 ⁇ m, although it depends on the type of physiologically active peptide contained in the composition, and is in the range of 1 to 500 ⁇ m that diffuses widely in the nasal cavity. Is more preferable, and the range of 20 to 200 ⁇ m is more preferable.
- the cellulose acetate retaining the physiologically active peptide of the present invention can be obtained, for example, by mixing and drying an aqueous solution of a physiologically active peptide dissolved in a preferred amount of water and cellulose acetate. It can also be obtained by mixing a powdered physiologically active peptide and cellulose acetate, or adding a preferred amount of water simultaneously with mixing and drying.
- any method for drying the cellulose acetate powder to which water containing a physiologically active peptide is added any method may be used as long as the purpose of the present invention is met, but it is desirable to use vacuum drying or freeze drying.
- water when mixing the physiologically active peptide and the base cellulose acetate.
- a solvent that does not dissolve cellulose acetate and can be mixed with water can be added.
- a mixed liquid of an alcohol, acetonitrile, acetone or the like in any ratio that satisfies the above conditions and water.
- the mixing amount of water is preferably 0.2 to 500 times (20 to 500%), more preferably 0.2 to 2.5 times (20 to 250%) with respect to the weight of cellulose acetate. In particular, it is preferably 1 to 2.5 times (100% to 250%) in view of easy handling of the composition at the time of mixing.
- a cellulose acetate powder holding a physiologically active peptide therein may be pulverized and sieved again to a desired particle size.
- cellulose acetate as a base material is used in combination with an arbitrary physiologically active peptide as a main ingredient.
- the physiologically active peptide means any substance that exhibits a desired effect in vivo, and is not particularly limited.
- bioactive peptides particularly bioactive peptides having a molecular weight of 20,000 or less, are suitably combined with cellulose acetate because of their relatively high absorption from the mucosa.
- the peptide whose mucosal permeability is enhanced includes various peptide drugs, and in particular, human glucagon-like peptide-1 (GLP-1), human parathyroid hormone (hPTH) and Its N-terminal fragment hPTH (1-34), human motilin, human ghrelin, human atrial natriuretic peptide, brain sodium peptide (BNP), C-type sodium peptide (CNP), human insulin, leptin, resistin, glucagon, relaxin, galanin, Gastrin, apelin, selectin, calcitonin, adrenomedullin, amylin, humanin, thymosin, endorphin, endomorphin, nocystatin, enkephalin, neuropeptide Y, neuropeptide S, neuromedin U, angiotensin, Endothelin, guanylin, salusin, urotensin, oxytocin, vaso
- the derivative herein refers to a physiologically active peptide in which substitution of one to several natural amino acids, in particular, conservative substitution and / or deletion or addition is performed based on a natural peptide sequence.
- the peptide may be commercially available, or, for example, in the case of a peptide consisting only of chemical synthesis, L-type natural amino acid, recombinant DNA technology, or a product produced by combining them is used. May be.
- composition of the present invention absorbs the physiologically active peptide from the blood vessels under the nasal mucosa immediately after administration into the body, and the time until drug effect is short, the onset time until drug effect is manifested after drug administration.
- physiologically active peptides whose short is useful therapeutically.
- the blending ratio of cellulose acetate and bioactive peptide in the composition of the present invention depends on various factors such as the type of bioactive peptide and the form of use of the composition, but the bioactive peptide is 0.01 to 50 of the entire composition.
- the cellulose acetate powder can be used in an amount of 50% to 100% by weight based on the weight.
- the dose by spraying or inhalation of the composition of the present invention is usually 0.1 to 500 mg / dose, preferably 1 to 100 mg / dose. Even at such a small dose, the composition of the present invention exhibits an excellent BA increasing action, and therefore a relatively large amount of absorption in the body (about 1 mg / person / time) is required to develop a physiologically active action. Even if it is an active peptide, it can absorb the amount required for the expression of drug efficacy.
- composition of the present invention can achieve an improvement in BA only by a combination of the above physiologically active peptide and cellulose acetate as a base.
- excipients, preservatives, preservatives and the like can be added as long as they do not adversely affect the purpose of the present invention.
- examples include lubricants such as talc, stearic acid and sodium salts, calcium salts, carplex, etc., binders such as starch and dextrin, pH regulators such as citric acid and glycine, preservatives such as ascorbic acid, etc.
- the agent include paraoxybenzoates, benzalkonium chloride, phenol, chlorobutanol and the like, and examples of the flavoring agent include menthol and citrus fragrance.
- cellulose acetate used as a base can be added as an excipient.
- an appropriate amount of the component can be added as long as it does not adversely affect the mucous membrane as a solid component other than the physiologically active peptide and cellulose acetate and does not prevent the absorption of the physiologically active peptide.
- composition of the present invention can be administered by spraying into the nasal cavity, and a predetermined amount of air or a gas that does not adversely affect the human body (air, nitrogen gas, argon gas, carbon dioxide gas, chlorofluorocarbon gas, etc.) What is necessary is just to spray in.
- air nitrogen gas, argon gas, carbon dioxide gas, chlorofluorocarbon gas, etc.
- any conventional nasal or pulmonary administration device can be used.
- a constant injection type pressurized administration device is filled with the composition of the present invention, and a constant amount is used.
- a method of spraying into the nasal cavity and the trachea one by one, filling a capsule or the like with a certain amount of the composition of the present invention, and mounting it on a pressure administration device as necessary so that the composition can be sprayed by perforation or the like In addition, a method of spraying in the nasal cavity, trachea, etc. with air or a gas that does not adversely affect the human body is conceivable.
- composition of the present invention when administered into the nasal cavity, it can also be performed by suction alone.
- the composition of the present invention is filled into capsules, blister packs, etc., in a certain amount, and when necessary, the suction device is used as it is.
- the composition can also reach the nasal cavity by being attached to and sucked.
- composition of the present invention is not limited to nasal administration, but can also be used for pulmonary administration, transpharyngeal mucosa, transbronchial mucosa administration, etc., using a conventional administration device according to the administration method. Can be administered.
- Example Method 1 Absorption test of nasal administration composition using cynomolgus monkey 1-1. Preparation of composition for nasal administration As a physiologically active polypeptide, glucagon-like peptide (hereinafter referred to as GLP-1), human parathyroid hormone 1-34 (hereinafter referred to as hPTH (1-34)), motilin derivative used. According to the methods described in Examples 1 to 10 and Comparative Examples 1 to 9, nasal absorption compositions containing various peptides were prepared. No. 2 gelatin capsules were filled so that the amount of each peptide was about 500 ⁇ g. GLP-1 and hPTH (1-34) were produced by a known gene recombination method and used for the test.
- Motilin is a peptide consisting of 22 amino acids.
- a motilin derivative a peptide represented by the formula (I) was produced by a known gene recombination method and used for testing.
- Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg-Leu-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Pro-Gln (I) (SEQ ID NO: 1 )
- Blood treatment method 1-3-1 Blood treatment when GLP-1 composition for nasal administration was administered Blood was collected by attaching a disposable syringe needle to a syringe barrel infiltrated with heparin sodium. Immediately after blood collection, add 1/100 volume of 10% EDTA ⁇ 2Na ⁇ 2H 2 O-saline solution and 1/100 volume of DPP IV Inhibitor, stir, ice-cool, centrifuge (4 ° C) and plasma Got.
- Blood treatment when hPTH (1-34) composition for nasal administration was administered Blood was collected by attaching a disposable syringe needle to a syringe barrel infiltrated with heparin sodium. Immediately after collection, 1/100 volume of 10% EDTA ⁇ 2Na ⁇ 2H 2 O-saline solution was added, stirred, ice-cooled, and centrifuged (4 ° C.) to obtain plasma. To the obtained plasma, an aprotinin solution of 1/10 of the plasma volume was added and stirred.
- Blood treatment when a composition for nasal administration of a motilin derivative was administered Blood was collected by attaching a disposable syringe needle to a syringe barrel infiltrated with heparin sodium. Immediately after collection, 1/100 volume of 10% EDTA ⁇ 2Na ⁇ 2H 2 O-saline solution was added, stirred, ice-cooled, and centrifuged (4 ° C.) to obtain plasma. To the obtained plasma, an aprotinin solution of 1/10 of the plasma volume was added and stirred.
- the plasma drug concentration of the collected plasma was measured by the following method.
- GLP-1 concentration in plasma was measured by enzyme immunoassay (ELISA method) using GLP-1 ELISA kit (Linco). The treatment was performed according to the kit protocol, and the absorbance at 355 nm / 460 nm was measured. BA was calculated by comparing the plasma concentration time after nasal administration-area under the curve (AUC) with AUC after intravenous administration of GLP-1 dissolved in 5% mannitol solution.
- AUC plasma concentration time after nasal administration-area under the curve
- Plasma hPTH (1-34) Concentration Plasma hPTH (1-34) concentration was measured using a radioimmunoassay method (RIA method). After anti-PTH antibody was added to the plasma sample, [ 125 I-Tyr34] hPTH (1-34) was added to cause a competitive reaction. A secondary antibody was added thereto to precipitate hPTH (1-34) bound to the anti-PTH antibody, and after separating the supernatant, the radioactivity in the precipitated fraction was measured with a ⁇ -counter (manufactured by Packard). BA was calculated by comparing the plasma concentration time-under-curve area (AUC) after nasal administration with AUC after intravenous administration of PTH dissolved in 5% mannitol solution.
- AUC plasma concentration time-under-curve area
- Plasma concentration of motilin derivative was measured by a radioimmunoassay method (RIA method) using an anti-human motilin antibody. That is, after anti-human motilin antibody was added to a plasma sample, 125 I-human motilin was added to cause a competitive reaction. A secondary antibody was added thereto to precipitate human motilin bound to the anti-human motilin antibody, and after separating the supernatant, the radioactivity in the precipitate fraction was measured with a ⁇ -counter (Perkin Elmer). BA was calculated by comparing the plasma concentration time after nasal administration-area under the curve (AUC) with AUC after intravenous administration of the motilin derivative dissolved in 5% mannitol solution.
- AUC plasma concentration time after nasal administration-area under the curve
- Cellulose acetate (manufactured by Eastman Chemical, CA398, acetyl group content 39.8%) was pulverized using a hammer mill (Hosokawa Micron, ACM-15H). The pulverized cellulose acetate was sieved using a vacuum suction type sieving apparatus (Hosokawa Micron Corporation, 200LS-N) to obtain a fraction of 40 to 100 ⁇ m. Hereinafter, unless otherwise specified, cellulose acetate obtained from this fraction was used as a base in the tests.
- crystalline cellulose (Asahi Kasei Chemicals, Theolas PH-101) was similarly sieved using a vacuum suction type sieving apparatus to obtain a fraction of 40 to 100 ⁇ m.
- crystalline cellulose of this fraction was used as a base for the tests.
- Example 1 100 mg of GLP-1 was dissolved in 4 mL of purified water. This solution and 4 g of cellulose acetate were kneaded with a spatula in a beaker and then dried to obtain a composition (GLP-1 solution mixed composition).
- Example 1 the monkey nasal absorbability of the compositions obtained in Example 1 and Comparative Examples 1 and 2 was evaluated. The results are shown in FIG. Further, the BAs of the compositions of Example 1, Comparative Example 1 and Comparative Example 2 were 57.9%, 48.4% and 38.2%, respectively.
- the GLP-1 solution mixture composition (Example 1) exhibits better absorbability than the GLP-1 solid mixture composition (Comparative Example 1) and the GLP-1 crystalline cellulose composition (Comparative Example 2). I understood that.
- Example 2 100 mg of hPTH (1-34) was dissolved in 4 mL of purified water. This solution and 4 g of cellulose acetate were kneaded with a spatula in a beaker and then dried to obtain a composition (hPTH solution mixed composition).
- Example 2 the nasal absorbability of the monkeys of the compositions obtained in Example 2 and Comparative Examples 3 and 4 was evaluated. The result is shown in FIG. Further, the BAs of the compositions of Example 2, Comparative Example 3 and Comparative Example 4 were 3.8%, 2.8% and 2.3%, respectively. It was found that the hPTH solution mixed composition (Example 2) exhibited better absorbability than the hPTH solid mixed composition (Comparative Example 3) and the hPTH crystalline cellulose composition (Comparative Example 4).
- Example 3 100 mg of motilin derivative was dissolved in 4 mL of purified water. This solution and 4 g of crystalline cellulose were kneaded with a spatula in a beaker and then dried to obtain a composition (motilin derivative solution mixed composition).
- Example 3 the nasal absorbability of monkeys of the compositions obtained in Example 3 and Comparative Examples 5 and 6 was evaluated. The results are shown in FIG. Further, the BAs of the compositions of Example 3, Comparative Example 5 and Comparative Example 6 were 4.6%, 4.0% and 3.3%, respectively.
- the motilin derivative solution mixed composition (Example 3) was found to exhibit better absorbability than the motilin derivative solid mixed composition (Comparative Example 5) and the motilin derivative crystalline cellulose composition (Comparative Example 6). .
- Example 4 After mixing 300 mg of motilin derivative and 12 g of cellulose acetate using a high-speed stirring granulator (Higuchi Shokai, PalmXer), 2.4 mL of purified water was dropped and kneaded while stirring was continued. Then, it dried and obtained the composition.
- Higuchi Shokai, PalmXer a high-speed stirring granulator
- Example 5 300 mg of motilin derivative was dissolved in 12 mL of purified water. Using a planetary stirrer (PRIMIX, HIVIS MIX), this solution was gradually added to 12 g of cellulose acetate and kneaded, and then dried to obtain a composition.
- PRIMIX planetary stirrer
- HIVIS MIX HIVIS MIX
- Example 6 25 mg of motilin derivative was dissolved in 2.5 mL of purified water. This solution and 1 g of cellulose acetate were kneaded with a spatula in a beaker and then dried to obtain a composition.
- Example 7 12.5 mg of motilin derivative was dissolved in 2.5 mL of purified water. This solution and 0.5 g of cellulose acetate were kneaded with a spatula in a beaker and then dried to obtain a composition.
- each composition was administered nasally so that a single dose was about 500 ⁇ g as a motilin derivative, and blood was collected over time.
- the results are shown in FIG. 4 and Table 1.
- the compositions of Examples 4 to 7 had a BA of 5% or more, while the compositions of Comparative Examples 7 to 8 were 4% or less. From this, it was found that the amount of water added to cellulose acetate is preferably 20% or more.
- Example 8 A composition was prepared using cellulose acetate (Eastman Chemical Co., acetyl group content 32.0%) having a different acetyl group content from the above cellulose acetate as a base.
- the cellulose acetate was pulverized with a pin mill (Nara Machinery Co., Ltd., sample mill).
- the pulverized cellulose acetate was sieved using a vacuum suction type sieving device (Hosokawa Micron Corporation, 200LS-N) to obtain a fraction of 40 to 100 ⁇ m.
- a solution in which 0.5 g of the obtained cellulose acetate powder and 12.5 mg of motilin derivative were dissolved in 0.5 mL of purified water was added to a beaker, kneaded using a spatula, and then dried to obtain a composition.
- Example 8 the monkey nasal absorbability of a powder composition using the cellulose acetate having an acetyl group content of 32.0% obtained in Example 8 as a base was evaluated. The results are shown in FIG. Further, the BA of the composition of Example 8 was 6.7%. It was found that good BA was exhibited using any cellulose acetate having an acetyl group content of 32.0% or 39.8%.
- Example 9 The motilin derivative used in Example 3 and the like was fluorescently labeled by the following method. First, 100 mg of motilin derivative (compound MT114) is dissolved in phosphate buffer (pH 8.3), and 10 mg of Fluorescein-5-EX N-hydroxysuccinimide ester (Sigma-Aldrich) dissolved in dimethyl sulfoxide is added and mixed. did. After the reaction, the resulting solution was subjected to solid phase extraction using Sep-Pak Plus CM Cartridges (Waters) and Sep-Pak Plus C18 Environmental Cartridges (Waters), and then lyophilized to obtain 37 mg of motilin derivative fluorescent label. Obtained. Thereafter, the motilin derivative and the fluorescently labeled motilin derivative were mixed at a ratio of 50: 1, dissolved in water, lyophilized and used for the preparation of the compositions of Example 10 and Comparative Example 9.
- phosphate buffer pH 8.3
- Example 10 A composition was prepared in the same manner as in Example 5 using the fluorescently labeled motilin derivative prepared in Example 9.
- cellulose acetate In order to examine the safety of cellulose acetate, the irritation of cynomolgus monkeys on the nasal mucosa was examined using cellulose acetate. 20 mg of cellulose acetate was administered intranasally 3 times a day for 2 weeks, and histological observation of the nasal mucosa was performed. As a result, no abnormality of the nasal mucosa was observed, and there was no problem in safety.
- the composition based on cellulose acetate of the present invention can improve the bioavailability of the bioactive peptide as the main agent when sprayed or inhaled onto mucous membranes such as in the nasal cavity.
- a composition capable of nasal administration which is a home-made and painless preparation form, with respect to a physiologically active peptide that has been provided only in a preparation form as an injection until now.
- cellulose acetate has low water absorbability, it can avoid discomfort such as nasal mums when using a highly water-absorbing base such as crystalline cellulose, and has excellent safety.
- a composition can be provided.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
1)生理活性ペプチドと、基剤としての酢酸セルロースを含有する経鼻投与用組成物。
2)前記生理活性ペプチドが基剤内に含浸されてなる、1)の組成物。
3)酢酸セルロースのアセチル化の程度が32~40%である1)又は2)の組成物。
4)前記生理活性ペプチドが分子量2万以下のペプチドである1)~3)のいずれかの組成物。
5)前記生理活性ペプチドがヒトグルカゴン様ペプチド-1(GLP-1)、ヒト副甲状腺ホルモン、ヒト副甲状腺ホルモン1-34(hPTH(1-34))、ヒトモチリン、ヒトモチリン誘導体、ヒトグレリン、ヒト心房性ナトリウム利尿ペプチド、脳性ナトリウムペプチド(BNP)、又はC型ナトリウムペプチド(CNP)である4)の組成物。
6)生理活性ペプチド、酢酸セルロース及び水を混合した後、続いて当該混合物を乾燥することで粉末状経鼻投与用組成物が製造される、1)~5)のいずれかの組成物の製造方法。
7)生理活性ペプチドと酢酸セルロースと水の混合において、使用される水の量が酢酸セルロースに対して重量比20%以上である6)の製造方法。
8)生理活性ペプチドと酢酸セルロースと水の混合において、使用される水の量が酢酸セルロースに対して重量比20%以上、250%以下である、7)の製造方法。
9)生理活性ペプチドと酢酸セルロースと水の混合において、使用される水の量が酢酸セルロースに対して重量比100%以上、250%以下である、8)の製造方法。
カニクイザルを用いた経鼻投与用組成物の吸収性試験
1-1.経鼻投与用組成物の調製
生理活性ポリペプチドとして、グルカゴン様ペプチド(以下、GLP-1)、ヒト副甲状腺ホルモン1-34(以下、hPTH(1-34))、モチリン誘導体を使用した。実施例1~10および比較例1~9に記載した方法に従って、各種ペプチドを含有する経鼻吸収用組成物を調製した。各ペプチドの量が約500 μgになるように2号ゼラチンカプセルに充填した。GLP-1およびhPTH(1-34)は公知技術の遺伝子組換え法により製造し、試験に使用した。モチリンは22個のアミノ酸からなるペプチドであり、本発明ではモチリン誘導体の一例として、式(I)で示されるペプチドを公知の遺伝子組換え法で製造し、試験に使用した。
Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg-Leu-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Pro-Gln (I)(配列番号1)
体重6 kg前後のカニクイザル(ハムリー株式会社)を用いた。試験前日から絶食し、試験当日にモンキーチェアに固定した。投与には鼻腔内噴霧デバイス(日立オートモティブシステム)を用いた。1カプセルを経鼻製剤用デバイスにセットし、吸気に合わせて5回ポンピングすることによりカニクイザルに経鼻投与した。投与後5、10、15、20、30、60、120、180分後に橈側皮静脈から下記の方法で採血を行った。
1-3-1. GLP-1経鼻投与用組成物を投与した場合の血液処理
ヘパリンナトリウムを浸潤させた注射筒にディスポーサブル注射針を装着し採血した。採血後速やかに1/100容量の10%EDTA・2Na・2H2O-生理食塩液及び1/100容量のDPP IV Inhibitorを加え、攪拌した後に氷冷し、遠心分離(4℃)して血漿を得た。
ヘパリンナトリウムを浸潤させた注射筒にディスポーサブル注射針を装着し採血した。採取後速やかに1/100容量の10%EDTA・2Na・2H2O-生理食塩液を加え、攪拌した後に氷冷し、遠心分離(4℃)して血漿を得た。得られた血漿には、血漿量の1/10量のアプロチニン溶液を加えて攪拌した。
ヘパリンナトリウムを浸潤させた注射筒にディスポーサブル注射針を装着し採血した。採取後速やかに1/100容量の10%EDTA・2Na・2H2O-生理食塩液を加え、攪拌した後に氷冷し、遠心分離(4℃)して血漿を得た。得られた血漿には、血漿量の1/10量のアプロチニン溶液を加えて攪拌した。
採取した血漿の血漿中薬物濃度測定を下記の方法で行った。
GLP-1ELISAキット(Linco)を用い、エンザイムイムノアッセイ法(ELISA法)で血漿中GLP-1濃度を測定した。キットのプロトコールに従って処理を行い、355 nm / 460 nmの吸光度を測定した。BAは、経鼻投与後の血漿中濃度時間-曲線下面積(AUC)を、5%マンニトール溶液に溶かしたGLP-1の静脈内投与後のAUCと比較して算出した。
ラジオイムノアッセイ法(RIA法)を用いて、血漿中hPTH(1-34)濃度を測定した。血漿試料に抗PTH抗体を加えたのち、[125I-Tyr34]hPTH(1-34)を加えて競合反応させた。これに二次抗体を加えて抗PTH抗体に結合したhPTH(1-34)を沈殿させ、上清分離後に沈殿画分中の放射能をγ-カウンター(パッカード社製)で測定した。BAは、経鼻投与後の血漿中濃度時間-曲線下面積(AUC)を、5%マンニトール溶液に溶かしたPTHの静脈内投与後のAUCと比較して算出した。
モチリン誘導体の血漿中濃度測定は、抗ヒトモチリン抗体を用いたラジオイムノアッセイ法(RIA法)により実施した。すなわち、血漿試料に抗ヒトモチリン抗体を加えたのち、125I-ヒトモチリンを加えて競合反応させた。これに二次抗体を加えて抗ヒトモチリン抗体に結合したヒトモチリンを沈殿させ、上清分離後に沈殿画分中の放射能をγ-カウンター(パーキンエルマー社製)で測定した。BAは、経鼻投与後の血漿中濃度時間-曲線下面積(AUC)を、5%マンニトール溶液に溶かしたモチリン誘導体の静脈内投与後のAUCと比較して算出した。
GLP-1 100 mgを精製水4 mLに溶解させた。ビーカー中でこの溶液と酢酸セルロース4 gを、スパーテルを用いて練合した後、乾燥して、組成物(GLP-1溶液混合組成物)を得た。
GLP-1 100 mgと酢酸セルロース 4 gを乳鉢に加えた。乳棒で30秒間混合した後、30秒間放冷するサイクルを3回繰り返し、組成物(GLP-1固体混合組成物)を得た。
GLP-1 100 mgを精製水4 mLに溶解させた。ビーカー中でこの溶液と結晶セルロース 4 gを、スパーテルを用いて練合した後、乾燥して、組成物(GLP-1結晶セルロース組成物)を得た。
hPTH(1-34)100 mgを精製水4 mLに溶解させた。ビーカー中でこの溶液と酢酸セルロース 4 gを、スパーテルを用いて練合した後、乾燥して、組成物(hPTH溶液混合組成物)を得た。
hPTH(1-34) 100 mgと酢酸セルロース 4 gを乳鉢に加えた。乳棒で30秒間混合した後、30秒間放冷するサイクルを3回繰り返し、組成物(hPTH固体混合組成物)を得た。
hPTH(1-34) 100 mgを精製水4 mLに溶解させた。ビーカー中でこの溶液と結晶セルロース 4 gを、スパーテルを用いて混合した後、乾燥して、組成物(hPTH結晶セルロース組成物)を得た。
モチリン誘導体100 mgを精製水4 mLに溶解させた。ビーカー中でこの溶液と結晶性セルロース 4 gを、スパーテルを用いて練合した後、乾燥して、組成物(モチリン誘導体溶液混合組成物)を得た。
モチリン誘導体100 mgと結晶セルロース4 gを乳鉢に加えた。乳棒で30秒間混合した後、30秒間放冷するサイクルを3回繰り返し、組成物(モチリン誘導体固体混合組成物)を得た。
モチリン誘導体100 mgを精製水4 mLに溶解させた。ビーカー中でこの溶液と結晶セルロース 4 gを、スパーテルを用いて練合した後、乾燥して、組成物(モチリン誘導体結晶セルロース組成物)を得た。
モチリン誘導体300 mgと酢酸セルロース 12 gを、高速攪拌造粒装置(樋口商会、PalmXer)を用いて混合した後、攪拌を続けながら精製水2.4 mLを滴下して練合した。その後、乾燥して組成物を得た。
モチリン誘導体300 mgを精製水12 mLに溶解させた。遊星式攪拌装置(PRIMIX、HIVIS MIX)を用いて、酢酸セルロース12 gにこの溶液を徐々に加えて練合した後、乾燥して組成物を得た。
モチリン誘導体25mgを精製水2.5 mLに溶解させた。ビーカー中でこの溶液と酢酸セルロース 1 gを、スパーテルを用いて練合した後、乾燥して、組成物を得た。
モチリン誘導体12.5 mgを精製水2.5 mLに溶解させた。ビーカー中でこの溶液と酢酸セルロース0.5 gを、スパーテルを用いて練合した後、乾燥して、組成物を得た。
モチリン誘導体10 mgと酢酸セルロース0.4 gを乳鉢に加えた。乳棒で30秒間混合した後、30秒間放冷するサイクルを3回繰り返し、組成物を得た。
モチリン誘導体50 mgと酢酸セルロース 2 gを乳鉢に加えた。乳棒で30秒間混合した後、30秒間放冷するサイクルを3回繰り返した後、精製水0.1 mLを加え混合後、乾燥して、組成物を得た。
基剤として上記の酢酸セルロースとはアセチル基含有率の異なる酢酸セルロース(イーストマンケミカル社、アセチル基含有率32.0%)を用いて組成物を作製した。当該酢酸セルロースを、ピンミル(奈良機械製作所、サンプルミル)で粉砕した。粉砕した酢酸セルロースは減圧吸引型篩い分け装置(ホソカワミクロン社、200LS-N)を用いて篩い分けを行い、40~100μmの画分を得た。得られた酢酸セルロース粉末0.5 gと、モチリン誘導体12.5 mgを精製水0.5 mLに溶解した溶液をビーカーに加え、スパーテルを用いて練合した後、乾燥して、組成物を得た。
実施例3などで使用したモチリン誘導体を以下の方法で蛍光標識した。まず、リン酸緩衝液(pH 8.3)にモチリン誘導体(化合物MT114)100 mgを溶解し、これにジメチルスルホキシドに溶解したFluorescein-5-EX N-hydroxysuccinimide ester(シグマ-アルドリッチ)10 mgを加えて混合した。反応後、得られた溶液からSep-Pak Plus CM Cartridges(ウォーターズ)およびSep-Pak Plus C18 Environmental Cartridges(ウォーターズ)を用いて固相抽出した後、凍結乾燥して、モチリン誘導体蛍光標識体37 mgを得た。その後、モチリン誘導体と蛍光標識モチリン誘導体を50:1の割合で混合し、水に溶解した後、凍結乾燥して実施例10および比較例9の組成物の調製に使用した。
実施例9で調製した蛍光標識モチリン誘導体を用いて、実施例5と同様に組成物を調製した。
実施例9で調製した蛍光標識モチリン誘導体を用いて、比較例7と同様に組成物を調製した。
Claims (9)
- 生理活性ペプチドと、基剤としての酢酸セルロースを含有する粉末状経鼻投与用組成物。
- 前記生理活性ペプチドが基剤内に含浸されてなる、請求項1に記載の組成物。
- 酢酸セルロースのアセチル化の程度が32~40%である請求項1又は2に記載の組成物。
- 前記生理活性ペプチドが分子量2万以下のペプチドである請求項1~3のいずれか1項に記載の組成物。
- 前記生理活性ペプチドがヒトグルカゴン様ペプチド-1、ヒト副甲状腺ホルモン(hPTH)、ヒト副甲状腺ホルモンhPTH(1-34)、ヒトモチリン、ヒトモチリン誘導体、ヒトグレリン、ヒト心房性ナトリウム利尿ペプチド、脳性ナトリウムペプチド(BNP)、又はC型ナトリウムペプチド(CNP)である請求項4に記載の組成物。
- 生理活性ペプチド、酢酸セルロース及び水を混合した後、続いて当該混合物を乾燥することで粉末状経鼻投与用組成物が製造される、請求項1~5のいずれか1項に記載の組成物の製造方法。
- 生理活性ペプチドと酢酸セルロースと水の混合において、使用される水の量が酢酸セルロースに対して重量比20%以上である請求項6に記載の組成物の製造方法。
- 生理活性ペプチドと酢酸セルロースと水の混合において、使用される水の量が酢酸セルロースに対して重量比20%以上、250%以下である請求項7に記載の組成物の製造方法。
- 生理活性ペプチドと酢酸セルロースと水の混合において、使用される水の量が酢酸セルロースに対して重量比100%以上、250%以下である請求項8に記載の組成物の製造方法。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012505769A JP5670430B2 (ja) | 2010-03-19 | 2011-03-18 | 経鼻投与用組成物及びその製造方法 |
CA2792749A CA2792749C (en) | 2010-03-19 | 2011-03-18 | Composition for nasal administration and method for preparing it |
US13/635,580 US8802622B2 (en) | 2010-03-19 | 2011-03-18 | Composition for nasal administration and method for preparing same |
BR112012023681A BR112012023681A2 (pt) | 2010-03-19 | 2011-03-18 | composição para administração nasal e método para prepará-la |
EP11756447.6A EP2548566B1 (en) | 2010-03-19 | 2011-03-18 | Composition for transnasal administration and method for producing same |
KR1020127024222A KR20130010462A (ko) | 2010-03-19 | 2011-03-18 | 경비 투여용 조성물 및 그 제조 방법 |
ES11756447.6T ES2663335T3 (es) | 2010-03-19 | 2011-03-18 | Composición para administración transnasal y método para prepararla |
CN201180024865.6A CN102905717B (zh) | 2010-03-19 | 2011-03-18 | 经鼻投与用组合物及其制造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010065042 | 2010-03-19 | ||
JP2010-065042 | 2010-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011115264A1 true WO2011115264A1 (ja) | 2011-09-22 |
Family
ID=44649344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/056625 WO2011115264A1 (ja) | 2010-03-19 | 2011-03-18 | 経鼻投与用組成物及びその製造方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8802622B2 (ja) |
EP (1) | EP2548566B1 (ja) |
JP (1) | JP5670430B2 (ja) |
KR (1) | KR20130010462A (ja) |
CN (1) | CN102905717B (ja) |
BR (1) | BR112012023681A2 (ja) |
CA (1) | CA2792749C (ja) |
ES (1) | ES2663335T3 (ja) |
WO (1) | WO2011115264A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2460826A1 (en) * | 2009-07-29 | 2012-06-06 | Daiichi Sankyo Company, Limited | Motilin-like peptide compound having transmucosal absorbability imparted thereto |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3970696A4 (en) * | 2019-05-16 | 2023-03-01 | Shin Nippon Biomedical Laboratories, Ltd. | POWDER PREPARATION FOR TRANSNASAL ADMINISTRATION AND MANUFACTURING METHOD THEREOF |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6242888B2 (ja) | 1984-04-24 | 1987-09-10 | Teijin Ltd | |
JPH07206699A (ja) | 1994-01-27 | 1995-08-08 | Teijin Ltd | ペプチド、蛋白質性薬物経鼻製剤 |
JPH1059841A (ja) | 1996-02-27 | 1998-03-03 | Teijin Ltd | 吸収性が改善された粉末状経鼻投与組成物 |
JP2003535042A (ja) * | 2000-01-20 | 2003-11-25 | バジリア ファルマスーチカ アーゲー | 鼻腔に投与可能な環式ペプチド組成物 |
WO2004078211A1 (ja) | 2003-03-04 | 2004-09-16 | Tanabe Seiyaku Co., Ltd. | 粉末経鼻投与製剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9020544D0 (en) * | 1990-09-20 | 1990-10-31 | Sandoz Ltd | Improvements in or relating to organic compounds |
ATE247456T1 (de) | 1996-02-27 | 2003-09-15 | Teijin Ltd | Puderförmige zusammensetzung zur nasalen anwendung |
SG177592A1 (en) * | 2009-07-29 | 2012-02-28 | Daiichi Sankyo Co Ltd | Motilin-like peptide compound having transmucosal absorbability imparted thereto |
-
2011
- 2011-03-18 KR KR1020127024222A patent/KR20130010462A/ko not_active Application Discontinuation
- 2011-03-18 BR BR112012023681A patent/BR112012023681A2/pt not_active IP Right Cessation
- 2011-03-18 EP EP11756447.6A patent/EP2548566B1/en active Active
- 2011-03-18 US US13/635,580 patent/US8802622B2/en not_active Expired - Fee Related
- 2011-03-18 CA CA2792749A patent/CA2792749C/en not_active Expired - Fee Related
- 2011-03-18 CN CN201180024865.6A patent/CN102905717B/zh not_active Expired - Fee Related
- 2011-03-18 WO PCT/JP2011/056625 patent/WO2011115264A1/ja active Application Filing
- 2011-03-18 ES ES11756447.6T patent/ES2663335T3/es active Active
- 2011-03-18 JP JP2012505769A patent/JP5670430B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6242888B2 (ja) | 1984-04-24 | 1987-09-10 | Teijin Ltd | |
JPH07206699A (ja) | 1994-01-27 | 1995-08-08 | Teijin Ltd | ペプチド、蛋白質性薬物経鼻製剤 |
JPH1059841A (ja) | 1996-02-27 | 1998-03-03 | Teijin Ltd | 吸収性が改善された粉末状経鼻投与組成物 |
JP2003535042A (ja) * | 2000-01-20 | 2003-11-25 | バジリア ファルマスーチカ アーゲー | 鼻腔に投与可能な環式ペプチド組成物 |
WO2004078211A1 (ja) | 2003-03-04 | 2004-09-16 | Tanabe Seiyaku Co., Ltd. | 粉末経鼻投与製剤 |
Non-Patent Citations (1)
Title |
---|
MELVILLE GN ET AL., RESPIRATION, vol. 40, no. 6, 1980, pages 329 - 336 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2460826A1 (en) * | 2009-07-29 | 2012-06-06 | Daiichi Sankyo Company, Limited | Motilin-like peptide compound having transmucosal absorbability imparted thereto |
EP2460826A4 (en) * | 2009-07-29 | 2013-11-20 | Daiichi Sankyo Co Ltd | MOTULINARY PEPTIDE COMPOUND WITH TRANSMUCOSAL ABSORBENT EQUIPMENT PROVIDED THEREFROM |
US8710184B2 (en) | 2009-07-29 | 2014-04-29 | Daiichi Sankyo Company, Limited | Motilin-like peptide compound having transmucosal absorbability imparted thereto |
Also Published As
Publication number | Publication date |
---|---|
EP2548566B1 (en) | 2018-02-21 |
KR20130010462A (ko) | 2013-01-28 |
US20130012439A1 (en) | 2013-01-10 |
BR112012023681A2 (pt) | 2018-05-15 |
CA2792749A1 (en) | 2011-09-22 |
JPWO2011115264A1 (ja) | 2013-07-04 |
JP5670430B2 (ja) | 2015-02-18 |
EP2548566A1 (en) | 2013-01-23 |
CA2792749C (en) | 2016-08-23 |
ES2663335T3 (es) | 2018-04-12 |
US8802622B2 (en) | 2014-08-12 |
EP2548566A4 (en) | 2014-06-25 |
CN102905717A (zh) | 2013-01-30 |
CN102905717B (zh) | 2016-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2327484C2 (ru) | Фармацевтическая композиция для назального всасывания | |
US5578567A (en) | Nasal pharmaceutical composition | |
US8278308B2 (en) | Diketopiperazine salts for drug delivery and related methods | |
RU2472492C2 (ru) | Стабильные неводные фармацевтические композиции | |
EP0364235A1 (en) | Physiologically active peptide composition for nasal administration | |
CA2430318C (en) | Powder formulation and method for producing the same | |
EP3434263B1 (en) | Method for preparing sustained release microparticle | |
EP3548508A1 (en) | New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists | |
TW201832783A (zh) | 包含glp-1/胰高血糖素雙重激動劑、連接子和透明質酸的接合物 | |
PT97610A (pt) | Processo para a preparacao de composicoes farmaceuticas contendo substancias biologicamente activas do grupo dos n-glicofurois | |
NO178564B (no) | Framgangsmåte for framstilling av et system for administrering av aktive medikamenter gjennom slimhinner | |
EP3434262B1 (en) | Method for preparing sustained-release microgranules | |
WO2015123997A1 (zh) | 含有降血糖活性成分的长效控释脂质体凝胶组合物及其制备方法 | |
JP2802488B2 (ja) | 経鼻吸収用生理活性ペプチド組成物 | |
US20120244196A1 (en) | Pharmaceutical composition containing medicament-containing fine particles and method for producing same | |
JP3770666B2 (ja) | 経粘膜吸収製剤用組成物 | |
JP5670430B2 (ja) | 経鼻投与用組成物及びその製造方法 | |
JP2021091693A (ja) | インスリン及びインスリン類似体の高純度吸入粒子、並びにそれらの高効率の製造方法 | |
WO2004078211A1 (ja) | 粉末経鼻投与製剤 | |
JPH0480008B2 (ja) | ||
JP2001172203A (ja) | 経肺投与用医薬品組成物 | |
CN106727448B (zh) | 醋酸奥曲肽干粉吸入制剂及其制备方法 | |
JP5264725B2 (ja) | ペプチド性薬物の粘膜吸収促進剤を含有する粘膜投与用組成物、及びその投与方法 | |
AU2012203627B2 (en) | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery | |
KR20110080085A (ko) | 지방산이 접합된 항당뇨펩티드로 표면 수식된 다공성 마이크로스피어 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180024865.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11756447 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2012505769 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2060/MUMNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2792749 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20127024222 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13635580 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011756447 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012023681 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012023681 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120919 |